REFERENCES
- Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–826.
- Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2007;44(1):1–9.
- Butturini A, Gale RP, Verlander PC, Hematologic abnormalities in Fanconi anemia. An International Fanconi Anemia Registry study. Blood. 1994;84:1650–1655.
- Alter BP. Cancer in Fanconi anemia, 1927–2001. Cancer. 2003;97(2):425–440.
- Alter BP. Fanconi's anemia and malignancies. Am J Hematol. 1996;53(2):99–110.
- Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2(6):446–457.
- De Chadarevian JP, Vekemans M, Bernstein M. Fanconi's anemia, medulloblastoma, Wilms’ tumor, horseshoe kidney, and gonadal dysgenesis. Arch Pathol Lab Med. 1985;109(4):367–369.
- Hirsch B, Shimamura A, Moreau L, Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood. 2007;103(7):2554–2559.
- Frappart PO, Lee Y, Lamont J, BRCA2 is required for neurogenesis and suppression of medulloblastoma. EMBO J. 2007;26(11):2732–2742.
- Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol. 1993;21(6):731–733.
- Cervenka J, Arthur D, Yasis C. Mitomycin C test for diagnostic differentiation of idiopathic aplastic anemia and Fanconi anemia. Pediatrics. 1981;67(1):119–127.
- Ruud E, Wesenberg F. Microcephalus, medulloblastoma and excessive toxicity from chemotherapy: an unusual presentation of Fanconi anaemia. Acta Paediatr. 2001;90(5):580–583.